Molecular Testing in Glioma (IDH1/2, MGMT)
EPTIS factsheet 794165 | Last revision 2020-10-23 | URL: https://www.eptis.bam.de/pts794165 https://www.eptis.bam.de/pts794165
PT provider | ||||||||||||||||
PT provider | RCPAQAP RCPAQAP | |||||||||||||||
Based in | Australia | |||||||||||||||
Language(s) | English | |||||||||||||||
Remarks | This module qualitatively assesses laboratory performance in the detection, reporting and interpretation of isocitrate dehydrogenase (IDH) 1 and 2 gene variants, and methylguanine-DNA Methyltransferase (MGMT) promoter methylation in glioma. What's new: This program is previously called IDH Mutation Analysis in Glioma. MGMT promoter methylation is now included in this module. | |||||||||||||||
Keywords | ||||||||||||||||
Product groups |
Human test material
|
|||||||||||||||
Testing fields |
Medical analysis
|
|||||||||||||||
Technical details | ||||||||||||||||
|
||||||||||||||||
Aims of the PT scheme | ||||||||||||||||
Target group of participants | ||||||||||||||||
Linked to specific legislation / standards | ||||||||||||||||
Additional, subsidiary aims | ||||||||||||||||
Number of participants | ||||||||||||||||
Accredited or otherwise reviewed by a 3rd party | ||||||||||||||||
Operation is commissioned / requested by | ||||||||||||||||
Fees and frequency | ||||||||||||||||
Participation fee | Yes | |||||||||||||||
Regularly operated | Yes (3 cases per survey/1 surveys) | |||||||||||||||
Year of first operation | ||||||||||||||||
Contact details of the PT provider | ||||||||||||||||
Provider | Contact person | |||||||||||||||
RCPAQAP
Suite 201/8 Herbert Street St Leonards, 2065 Australia Phone: (61 2) 9045 6000 Fax: (61 2) 9356 2003 Web: https://www.rcpaqap.com.au/ https://www.rcpaqap.com.au/ |
Mr Rhys Judd
Phone: (61 2) 9045 6000 Fax: (61 2) 9356 2003 Email: rhys.judd@rcpaqap.com.au rhys.judd@rcpaqap.com.au |